Literature DB >> 27558600

Integration-free T cell-derived human induced pluripotent stem cells (iPSCs) from a patient with recessive dystrophic epidermolysis bullosa (RDEB) carrying two compound heterozygous mutations in the COL7A1 gene.

Munenari Itoh1, Shiho Kawagoe2, Katsuto Tamai3, Hirotaka James Okano4, Hidemi Nakagawa2.   

Abstract

Expanded human T cells from a Japanese female with recessive dystrophic epidermolysis bullosa (RDBE) were used to generate integration-free induced pluripotent stem cells (iPSCs) by exogenous expression of four reprogramming factors, OCT3/4, SOX2, cMYC, KLF4, using Sendai virus vector (SeVdp). The authenticity of established iPSC line, RDEB-iPSC26, was confirmed by the expressions of stem cell markers and the differentiation capability into three germ layer. RDEB-iPSC26 may be a useful cell resource for the establishment of in vitro RDEB modeling and the study for developing gene and cell therapy.
Copyright © 2016 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Year:  2016        PMID: 27558600     DOI: 10.1016/j.scr.2016.05.003

Source DB:  PubMed          Journal:  Stem Cell Res        ISSN: 1873-5061            Impact factor:   2.020


  3 in total

Review 1.  Inside out: regenerative medicine for recessive dystrophic epidermolysis bullosa.

Authors:  Michael Vanden Oever; Kirk Twaroski; Mark J Osborn; John E Wagner; Jakub Tolar
Journal:  Pediatr Res       Date:  2017-11-01       Impact factor: 3.756

2.  CRISPR/Cas9-based targeted genome editing for correction of recessive dystrophic epidermolysis bullosa using iPS cells.

Authors:  Joanna Jacków; Zongyou Guo; Corey Hansen; Hasan E Abaci; Yanne S Doucet; Jung U Shin; Ryota Hayashi; Dominick DeLorenzo; Yudai Kabata; Satoru Shinkuma; Julio C Salas-Alanis; Angela M Christiano
Journal:  Proc Natl Acad Sci U S A       Date:  2019-12-09       Impact factor: 11.205

Review 3.  Stem Cells in Cardiovascular Medicine: the Road to Regenerative Therapies.

Authors:  Christopher W Anderson; Nicole Boardman; Jiesi Luo; Jinkyu Park; Yibing Qyang
Journal:  Curr Cardiol Rep       Date:  2017-04       Impact factor: 2.931

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.